Product Description
AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23847256/)
Mechanisms of Action: JAK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Myelofibrosis|Myeloproliferative Disorders
Phase 1: Thrombocytosis|Myelofibrosis|Thrombocythemia, Essential|Polycythemia Vera|Non-Small-Cell Lung Cancer|Myeloproliferative Disorders|Hepatocellular Carcinoma|Gastrointestinal Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| D1060C00004 | P1 |
Terminated |
Hepatocellular Carcinoma|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer |
2012-12-01 |
2019-03-19 |
Treatments |
|
| D1060C00002 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2012-09-01 |
2019-03-19 |
||
| D1060C00001 | P1 |
Completed |
Thrombocytosis|Myelofibrosis|Myeloproliferative Disorders|Polycythemia Vera|Thrombocythemia, Essential |
2012-03-01 |
2019-03-18 |
Treatments |
|
| 2007-006647-45 | P2 |
Completed |
Myeloproliferative Disorders|Myelofibrosis |
2014-08-25 |
2022-03-12 |